Rallybio Corporation is a clinical-stage biotechnology company focused on developing therapies for severe and rare diseases, specifically targeting disorders of complement dysregulation and hematology. Its lead program, RLYB116, is a once-weekly, subcutaneously injected complement component 5 (C5) inhibitor designed to treat conditions such as paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and neuromyelitis optica spectrum disorder. The company is also advancing RLYB332, a long-acting matriptase-2 antibody in preclinical development for the treatment of diseases of iron overload, including polycythemia vera and beta thalassemia. In March 2026, Rallybio entered into a merger agreement with Candid, a clinical-stage biotechnology company developing T-cell engager therapeutics for autoimmune diseases, which is intended to result in Candid becoming a wholly owned subsidiary of Rallybio. The company’s team includes leaders with prior experience in securing approvals for C5 inhibitors such as Soliris and Ultomiris.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage rallybio.com
Sector Healthcare IR page investors.rallybio.com
Tags
complement dysregulation, hematology, rare diseases, c5 inhibitors, iron overload, matriptase-2, subcutaneous injection, clinical-stage, autoimmune diseases, t-cell engagers, RLYB116, RLYB332, RLYB331, Candid, Farmington Merger Sub Inc., Soliris, Ultomiris, Recursion Pharmaceuticals Inc., Exscientia Ventures I Inc., Rallybio IPB LLC
Press page —

Metrics

Valuation  
Market cap $ 85.544M
Market cap (USD) $ 85.544M
P/E 3.94
PEG —
P/BV 0.93
P/S 99.70
P/OCF 2.76
P/FCF -2.87
Dividend yield —
Turnover / mcap —
Returns  
ROE -15.0%
ROI -33.7%
ROIC -93.0%
Profit margin -1,046.4%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock —
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 19
Quality score 7.1%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue 858K 600K — — — —
Net profit -8.978M -57.775M -74.564M -66.654M -47.013M -26.447M
Free cash flow -29.813M -49.282M -60.277M -57.338M -45.866M -22.176M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Share price — — 5.21 12.5 9.21 —
Price performance 12m — — -0.58 0.36 — —

Filed figures

Figure Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Lease liabilities (USD) — 0.00 555,000 392,000 154,000 176,000
Cash and deposits (USD) 140M 175M 57M 24.5M 13.9M 31.4M
Right-of-use assets (USD) — 700,000 524,000 346,000 152,000 175,000
Cash flow detail
Operating cash flow (USD) -22M -45.5M -57.3M -60.3M -49.3M -29.8M
Purchases of property, plant and equipment (USD) -137,000 -333,000 -54,000 -12,000 0.00 —
Change in payables (cash effect) (USD) 723,000 -976,000 487,000 -99,000 -698,000 -152,000
Income taxes paid (cash effect) (USD) — — — — 0.00 0.00
Share-based compensation (USD) 704,000 3.65M 9.5M 10.9M 7.99M 5.31M
Free cash flow (OCF - PPE - intangibles) (USD) -22.2M -45.9M -57.3M -60.3M -49.3M —
Income detail
Research and development expense (USD) 17.6M 26.9M 40.7M 53.5M 41.5M 19.6M
↳ 5y CAGR +2.1%
Total comprehensive income (USD) -26.4M -47M -66.9M -74.3M -57.7M -9.03M
Comprehensive income to owners (USD) -26.4M -47M -66.9M -74.3M -57.7M -9.03M
Reported Mar 15, 2022 May 10, 2022 Mar 6, 2023 Mar 12, 2024 Mar 16, 2026 Mar 16, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Rallybio Corporation — Other Events Bull 0 Bear 0 Routine

Rallybio Corporation (the “Company”) announced today that, subject to the satisfaction or waiver of any outstanding closing conditions, it anticipates the transactions contemplated by the Agreement and Plan of Merger and Reorganization (the “Merger Agreement”), dated as of May 31, 2026, by and among the Company, Avenzo Therapeutics, Inc. and Farmington Merger Sub, Inc., will close following the close of trading on November 20, 2026. The Company received approval from the Listing Qualifications department of The Nasdaq Stock Market to list its common stock on the Nasdaq Capital Market in connection with the Merger. The Company also announced updates about its previously announced special cash distribution of $13.90 per share (the “Cash Distribution”). The Cash Distribution will continue to be payable in cash to stockholders and pre-funded warrant holders of record as of November 5, 2026 (the “Distribution Record Date”), subject to the Nasdaq due bill procedures described below, then based on their holdings as of the Distribution Record Date and during the Due Bill Period (as defined below).

EAST BERLIN, Conn., November 10, 2026 – Rallybio Corporation (Nasdaq: RLYB) today announced that it will effect a one-for-two reverse stock split of its issued and outstanding common stock in connection with the transactions contemplated by the Agreement and Plan of Merger and Reorganization, dated as of May 31, 2026, among Rallybio, Avenzo Therapeutics, Inc. (“Avenzo”) and Farmington Merger Sub, Inc., a wholly owned subsidiary of Rallybio (the “Merger Agreement”). At Rallybio’s Annual Meeting of Stockholders held on November 4, 2026, stockholders approved an amendment to Rallybio’s Amended and Restated Certificate of Incorporation to effect a reverse stock split at a ratio ranging from one-for-two to one-for-nine, inclusive, with the final ratio to be mutually determined by Rallybio and Avenzo. On November 8, 2026, Rallybio’s Board of Directors, with Avenzo’s mutual agreement, approved a one-for-two reverse stock split of Rallybio’s issued and outstanding common stock. The reverse stock split is expected to become effective at 12:01 a.m., Eastern Time, on November 20, 2026, prior to the anticipated completion of the merger contemplated by the Merger Agreement (the “Merger”).

Rallybio Corporation — Other Events Bull 0 Bear 5 Distress

Rallybio Corporation (the “Company”) previously disclosed that, subject to the satisfaction or waiver of any outstanding closing conditions, the Company anticipated the transactions contemplated by the Agreement and Plan of Merger and Reorganization, dated as of May 31, 2026 (the “Merger Agreement”), by and among the Company, Avenzo Therapeutics, Inc. and Farmington Merger Sub, Inc., to close on November 6, 2026. Certain conditions related to the listing of the Company’s shares following the closing of the transactions have not been satisfied and, as a result, the parties have determined to postpone the closing to continue seeking the applicable listing approvals. In light of the postponement of the closing of the transactions, the Company did not deposit the funds for the previously announced cash distribution with Computershare on November 5, 2026. As a result, the previously announced payment date and ex-dividend date for the cash distribution may be delayed. The Company will provide further updates it deems appropriate or necessary in accordance with the applicable law and regulations.

Prompts

Rallybio Corporation (ticker RLYB), listed in United States.

ETFs Holding Rallybio Corporation

ETF Weight in ETF Shares Market value As of
DFAS 0.00% 6,675 $ 104.464K Nov 12, 2026
DXUV 0.00% 719 $ 11.252K Nov 12, 2026
DCOR 0.00% 684 $ 10.705K Nov 12, 2026
DFAC 0.00% 578 $ 9,045.70 Nov 12, 2026
AVSC 0.00% 1,562 $ 24.094K Nov 16, 2026